Mspl polymorphism at +83 bp in intron 1 of the human apolipoprote in A1 gene is associated with elevated levels of HDL cholesterol and apolipoprotein A1 in nondiabetic subjects but not in type 2 diabetic patients with coronary heart disease

Diabetes Care

Volumn 23, Issue 6, 2000, Pages 791-795

  Pulkkinen, Arto ^a   Viitanen, Laura ^a   Kareinen, Anu ^a   Lehto, Seppo ^a   Laakso, Markku ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; APOLIPOPROTEIN B; TRIACYLGLYCEROL; TYPE II SITE SPECIFIC DEOXYRIBONUCLEASE;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; INTRON; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; BLOOD; BLOOD PRESSURE; CORONARY ARTERY DISEASE; DIABETIC ANGIOPATHY; GENETICS; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; REFERENCE VALUE;

APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLESTEROL, HDL; CORONARY DISEASE; DEOXYRIBONUCLEASE HPAII; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; GENOTYPE; HUMANS; INTRONS; MALE; MIDDLE AGED; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; REFERENCE VALUES; TRIGLYCERIDES;

EID: 0033625376     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.23.6.791     Document Type: Article

References (30)

1. Forte TM, McCall MR: The role of apolipoprotein A-I-containing lipoproteins in atherosclerosis. Curr Opin Lipidol 5: 354-364, 1994
2. Wilson PW, Anderson KM, Harris T, Kannel WB, Castelli WP: Determinants of change in total cholesterol and HDL-C with age: the Framingham Study. J Gerontol 49: M252-M257, 1994
3. Sigurdsson G Jr, Gudnason V, Sigurdsson G, Humphries SE: Interaction between a polymorphism of the apo A-1 promoter region and smoking determines plasma levels of HDL and apo A-1. Arterioscler Thromb 12:1017-1022, 1992
4. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, et al.: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317: 1237-1245, 1987
5. Wang XL, Badenhop R, Humphrey KE, Wilcken DE: C to T and/or G to A transitions are responsible for loss of a MspI restriction site at the 5′-end of the human apolipoprotein A1 gene. Hum Genet 95: 473-474, 1995
6. Wang XL, Badenhop R, Humphrey KE, Wilcken DE: New MspI polymorphism at +83 bp of the human apolipoprotein A1 gene: association with increased circulating high density lipoprotein cholesterol levels. Genet Epidemiol 13:1-10, 1996
7. Talmud PJ, Ye S, Humphries SE: Polymorphism in the promoter region of the apolipoprotein A1 gene associated with differences in apolipoprotein A1 levels: the European Atherosclerosis Research Study. Genet Epidemiol 11:265-280, 1994
8. Wang XL, Liu SX, McCredie RM, Wilcken DE: Polymorphisms at the 5′-end of the apolipoprotein A1 gene and severity of coronary artery disease. J Clin Invest 98: 372-377, 1996
9. Minnich A, DeLangavant G, Lavigne J, Roederer G, Lussier-Cacan S, Davignon J: G→A substitution at position - 75 of the apolipoprotein A-1 gene promoter: evidence against a direct effect on HDL cholesterol levels. Arterioscler Thromb Vasc Biol 15:1740-1745, 1995
10. Saha N, Tay JS, Low PS, Humphries SE: Guanidine to adenine (G/A) substitution in the promoter region of the apolipoprotein A1 gene is associated with elevated serum apolipoprotein A1 levels in Chinese nonsmokers. Genet Epidemiol 11:255-264, 1994
11. Meng QH, Pajukanta P, Valsta L, Aro A, Pietinen P, Tikkanen MJ: Influence of apolipoprotein A-1 promoter polymorphism on lipid levels and responses to dietary change in Finnish adults. J Intern Med 241:373-378, 1997
12. de la Chapelle A: Disease gene mapping in isolated human populations: the example of Finland. J Med Genet 30:857-865, 1993
13. Kittles RA, Perola M, Peltonen L, Bergen AW, Aragon RA, Virkkunen M, Linnoila M, Goldman D, Long JC: Dual origins of Finns revealed by Y chromosome haplotype variation. Am J Hum Genet 62:1171-1179, 1998
14. World Health Organization: Diabetes Mellitus: Report of a WHO Study Group. Geneva, World Health Org., 1985 (Tech. Rep. Ser., no. 727)
15. World Health Organization: Proposal for the Multinational Monitoring of Trends and Determinants in Cardiovascular Disease and Protocol (MONICA Project). Geneva, World Health Org., 1983 (WHO/MNC/82.1, Rev. 1)
16. Haffner SM, Karhapää P, Mykkänen L, Laakso M: Insulin resistance, body fat distribution, and sex hormones in men. Diabetes 43:212-219, 1994
17. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215, 1988
18. Paul-Hayase H, Rosseneu M, Robinson D, Van Bervliet JP, Deslypere JP, Humphries SE: Polymorphisms in the apolipoprotein (apo) A1-CIII-A1V gene cluster: dertection of genetic variation determining plasma apo A1, apo CIII and apo A1V concentrations. Hum Genet 88:439-446, 1992
19. Penttilä IM, Voutilainen E, Laitinen P, Juutilainen P: Comparison of different analytical and precipitation methods for direct estimation of serum high-density lipoprotein cholesterol. Scand J Clin Lab Invest 41: 353-360, 1981
20. Laakso M, Sarlund H, Mykkänen L: Insulin resistance is associated with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance. Arteriosclerosis 10:223-231, 1990
21. Fruchart JC, Kora I, Cachera C, 0Clavey V, Duthilleul P, Moschetto Y: Simultaneous measurement of plasma apolipoproteins A-I and B by electroimmunoassay. Clin Chem 28:59-62, 1982
22. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH: A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 325: 373-381, 1991
23. Tribble DL, Krauss RM: HDL and coronary artery disease. Adv Intern Med 38:1-29, 1993
24. Steinmetz J, Boerwinkle E, Gueguen R, Visvikis S, Henny J, Siest G: Multivariate genetic analysis of high density lipoprotein particles. Atherosclerosis 92:219-227, 1992
25. Shemer R, Walsh A, Eisenberg S, Breslow JL, Razin A: Tissue-specific methylation patterns and expression of the human apolipoprotein A1 gene. J Biol Chem 265: 1010-1015, 1990
26. Kozak M: Structural features in eukaryotic mRNAs that modulate the initiation of translation J Biol Chem 266:19867-19870, 1991
27. Falcone D, Andrews DW: Both the 5′ untranslated region and the sequences surrounding the start site contribute to efficient initiation of translation in vitro. Mol Cell Biol 11:2656-2664, 1991
28. Juo SH, Wyszynski DF, Beaty TH, Huang HY, Bailey-Wilson JE: Mild association between the A/G polymorphism in the promoter of the apolipoprotein A-I gene and apolipoprotein A-I levels: a meta-analysis. Am J Med Genet 82:235-241, 1999
29. Kamboh MI, Aston CE, Nestlerode CM, McAllister AE, Hamman RF: Haplotype analysis of two APOA1/MspI polymorphisms in relation to plasma levels of apo A-I and HDL-cholesterol. Atherosclerosis 127:255-262, 1996
30. Jeenah M, Kessling A, Miller N, Humphries S: G to A substitution in the promoter region of the apolipoprotein A1 gene is associated with elevated serum apolipoprotein A1 and high density lipoprotein cholesterol concentrations. Mol Biol Med 7: 233-241, 1990